Long-term outcomes of 125 patients with metastatic pheochromocytoma or paraganglioma treated with 131I-mIBG.

CONCLUSIONS: Imaging, symptomatic and laboratory response to multimodal treatment including high dose 131 I-MIBG were achieved on long-term follow up in metastatic pheochromocytoma or paraganglioma. Imaging response at 3-6 months was prognostic. PMID: 31614368 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31614368?dopt=Abstract

Source: The Journal of Clinical Endocrinology and Metabolism - October 15, 2019 Category: Endocrinology Authors: Thorpe MP, Kane A, Zhu J, Morse MA, Wong T, Borges-Neto S Tags: J Clin Endocrinol Metab Source Type: research